Alembic Pharma Reports 17% Growth in Q4 Sales

7 May 2025 , 11:20 AM

Alembic Pharmaceuticals Ltd. announced its consolidated third quarter results ended March 31, 2025, which recorded good performance in core business operations. The company’s net sales grew 17% YoY at ₹1,770 crore with good growth in India-branded and international businesses.

EBITDA was up 9% at ₹286 crore, with EBITDA margin at 16% of total sales, reflecting operating efficiency. Profit prior to tax was higher by 5% at ₹192 crore, whereas net profit during the quarter was ₹157 crore.

MD Shaunak Amin noted that growth was based on improved performance in specialty treatments in India-branded operations and consistent resilience of the Animal Health business.

He further added that Alembic is emphasizing increased engagement with healthcare professionals and an expanding pipeline of products, which provides a solid platform for long-term growth.

India Branded Business posted an 8% YoY growth to ₹545 crore in the quarter. There was good performance in therapeutic segments such as gynaecology, anti-diabetic, ophthalmology, and dermatology. Anti-infective segment posted a growth of 7%, and cough and cold segment posted a growth of 11%.

Alembic Pharma launched 4 new products during the quarter, which brought year-to-date launches to 14, and new products posting good performance and good future trends.

The Animal Health business grew by 19%, beating expectations once again with a portfolio of established and well-known brands. The US generic business in the global marketplace grew by 20%, at ₹508 crore for the quarter, driven by 4 product launches. The Ex-US international generics business grew by 43% to ₹375 crore, reflecting expansion in many international markets.

The firm added 2 new ANDA approvals to bring the total number of ANDA approvals to 220, strengthening its US regulatory pipeline. In the API (Active Pharmaceutical Ingredient) segment, Alembic posted a 4% YoY growth with revenues of ₹342 crore for the quarter. The segment is a good top line contributor with steady international demand.

Alembic Pharmaceuticals, founded in 1907 with Indian centers, continues to be a industry-leading player of branded generics. Alembic has over 5,500 field professionals and has facilities in state-of-the-art R&D and manufacturing facilities certified by leading international regulators such as the US FDA.